39075-78-0Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS
-
Paragraph 0461; 0462, (2018/08/30)
The invention provides compounds of formula Ia′, Ib′, Ic′, and Id′: and pharmaceutically acceptable salts thereof, wherein the variables A, R6, R7, R8, R9, Rx, L, X, Y, and Z have the meaning as described herein. The compounds are useful for reducing endoplasmic reticulum stress and for producing analgesia in an animal.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS
-
Paragraph 0121; 0122, (2015/11/16)
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucus diseases related to painful inflammation and ulceration of the digestive tract lining and in the mouth.
A traceless linker approach to the solid phase synthesis of substituted guanidines utilizing a novel acyl isothiocyanate resin
Wilson, Lawrence J.,Klopfenstein, Sean R.,Li, Min
, p. 3999 - 4002 (2007/10/03)
Solid phase synthesis of a series of substituted guanidines based on a novel acyl isothiocyanate resin is presented. This method provides both mono and disubstituted guanidines with a variety of sterically demanding and/or electron withdrawing substituents in good purities and yields.
